{"schema_version":"secwatch.filing_event.v1","accession":"0001339970-26-000042","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2026-07-31T20:44:28+00:00","discovered_at":"2026-07-31T20:45:00.267202+00:00","generated_at":"2026-07-31T20:45:07.066283+00:00","sec_items":["1.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"aTyr Pharma regains global rights to efzofitimod after Kyorin termination","bullets":["Kyorin terminated collaboration; aTyr and Kyorin entered termination agreement effective July 30, 2026.","Exclusive rights to develop and commercialize efzofitimod in Japan revert to aTyr.","aTyr now holds global rights to efzofitimod for all forms of interstitial lung disease.","Termination includes wind-down of ancillary agreements and transfer of data and orphan drug designation.","No outstanding payments from Kyorin to aTyr regarding development costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001339970-26-000042","json":"https://secwatch.observer/filing/0001339970-26-000042.json","markdown":"https://secwatch.observer/filing/0001339970-26-000042.md","text":"https://secwatch.observer/filing/0001339970-26-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000042/0001339970-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000042/atyr-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T20:45:07.066283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}